Alumis Psoriasis Drug Achieves 90% Skin Clearance in Phase 3 Trials

Alumis (ALMS) announces breakthrough Phase 3 results for envudeucitinib, a new oral medication for moderate-to-severe plaque psoriasis showing exceptional skin clearance rates.